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Abstract The use of pre-implantation genetic diagnosis
(PGD) for hereditary cancer is subject to on-going debate,
particularly among professionals. This study evaluates the
attitude towards PGD and attitude-associated characteris-
tics of those concerned: family members with a hereditary
cancer predisposition. Forty-eight Von Hippel-Lindau and
18 Li–Fraumeni Syndrome families were identified via the
9 family cancer clinics in the Netherlands. In total, 216
high risk family members and partners were approached, of
whom 179 (83%) completed a self-report questionnaire. Of
the high risk family members, 35% expressed a positive
attitude towards PGD. Those with a current desire to have
children were significantly more likely to have a positive
attitude: 48% would consider the use of PGD. No other
sociodemographic, medical or psychosocial variables were
associated significantly with a positive attitude. The most
frequently reported advantage of PGD is the avoidance of a
possible pregnancy termination. Uncertainty about late
effects was the most frequently reported disadvantage.
These results indicate that approximately half of those
contemplating a future pregnancy would consider the use
of PGD. The actual uptake, however, is expected to be
lower. There is no indication that psychosocial factors
affect interest in PGD.
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Introduction
Family planning is one of the motives to undergo genetic
testing for a hereditary cancer predisposition [1]. Family
members at high risk are confronted with the actual pos-
sibility that they will transmit the cancer predisposition to
their offspring. This can play an important role in repro-
ductive decision-making.
Carriers of a hereditary cancer predisposition have up to
six options with regard to reproductive decision making,
namely: (1) to remain childless; (2) to have children and
accept the 50% risk of their child inheriting the cancer
predisposition; (3) to adopt a child; (4) to pursue gamete
donation; (5) to undergo prenatal diagnosis (PND), with the
possibility of pregnancy termination; or (6) to undergo pre-
implantation genetic diagnosis (PGD).
The last of these options, PGD, is a modern technique in
reproductive medicine that involves in vitro fertilization
(IVF) treatment followed by testing of 3-day old embryos
for the familial genetic predisposition. Subsequently, only
unaffected embryos are transferred to the uterus [2, 3].
Although PGD has been performed for all major hereditary
cancer syndromes [4], its use remains socially, ethically
and politically controversial [5–9]. Recently, controversy
about the use of PGD for hereditary cancer almost led to a
cabinet crisis in the Netherlands [10]. One of the issues of
debate concerned the circumstances under which the use of
PGD is appropriate and acceptable. In particular, concern
was expressed about a ‘slippery slope’ if PGD is to be used
for susceptibilities (i.e., risks) rather than certainties.
The discussion about the use of PGD for hereditary
cancer predispositions has been dominated by experts,
including clinicians, geneticists, and ethicists. The lay
perspective on PGD, and particularly that of members of
families with a known hereditary cancer predisposition, is
relatively unexplored. To date, four studies (one British
and three American) have investigated family members’
attitudes towards the use of PGD for hereditary cancer
predispositions. In a small study (N = 20) of familial
adenomatous polyposis (FAP), Kastrinos et al. [11] repor-
ted that all respondents were open to any form of prenatal
testing for FAP-carriers, and that 90% of the respondents
would personally consider the use of PGD. Menon et al.
[12] found that 75% of a sample of BRCA gene mutation
carriers (N = 52) considered it acceptable to offer PGD for
hereditary breast and ovarian cancer (HBOC), and that
14% would personally consider its use. Recently, among
111 female conference attendees with either a personal or
family history of breast and/or ovarian cancer, 57%
believed that PGD is acceptable for BRCA 1/2 carriers;
33% would personally consider its use [13]. Finally, among
213 members of the advocacy group that organized the
aforementioned conference, 13% indicated that they would
consider the use of PGD [14].
In summary, these previous studies have reported rela-
tively high levels of general acceptance of PGD for
hereditary cancer, and a wide range of personal interest in
its use (ranging from 13 to 90%). However, all previous
studies employed selective samples, almost all study par-
ticipants were women, and none of the studies included
spouses/partners. Additionally, in three studies sample
sizes were relatively small and response rates were only
moderate (ranging from 51 to 59%) [11–13]. Finally, little
information is available on the characteristics of individ-
uals with a positive vs. negative attitude towards PGD. For
example, are those who hold a positive attitude towards
PGD more likely to have a personal history of cancer, to
have high levels of cancer-related distress, or to have had
highly negative experiences with the disease in their
family?
The current study included a large sample of both male
and female high-risk individuals from families with a
known hereditary cancer predisposition, as well as their
partners. In this study we focused on two hereditary cancer
syndromes: Von Hippel-Lindau disease (VHL) and Li–
Fraumeni Syndrome (LFS). VHL and LFS are both rare
autosomal dominantly inherited tumor susceptibility syn-
dromes, characterized by an increased risk of developing a
broad spectrum of tumors. LFS is associated with germline
mutations in the TP53 gene [15]; the causative mutation of
VHL is a germline mutation in the VHL-gene [16]. LFS
tumors are malignant and include soft-tissue sarcomas,
osteosarcomas, early-onset breast cancer, acute leukemia,
adrenocortical neoplasm’s, central nervous system tumors,
pancreatic cancer and Wilm’s tumors [17–19]. Tumors
occurring in VHL are both benign and malignant, including
hemangioblastomas of the retina, cerebellum and spinal
cord, pheochromocytomas, renal cysts, renal clear cell
carcinomas and cysts and endocrine tumors of the pancreas
[20, 21]. VHL and LFS carriers have up to a 90% life-time
risk of developing clinically relevant signs and symptoms.
The age of onset of tumors varies widely (from early
childhood to adulthood). There are no preventive treatment
options available for VHL family members. The only
preventive option for female LFS family members is pro-
phylactic mastectomy to reduce the risk of breast cancer. In
fact, for all VHL, and the majority of LFS affected indi-
viduals, treatment is available after clinical relevant
expression of the disease only. In an effort to detect
expression of the disease at an early stage, periodic
screening is offered to high risk family members.
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The aim of our study was to investigate the attitudes of
VHL and LFS family members towards PGD, and to
identify characteristics associated significantly with a
positive attitude towards its use.
Materials and methods
Study sample
This study is part of a large, nationwide, cross-sectional
investigation of the psychosocial issues in VHL and LFS
carried out in collaboration with the nine family cancer
clinics in the Netherlands and the DNA-laboratories of the
University Medical Centre Utrecht, the Erasmus Medical
Centre, and the Netherlands Cancer Institute. Forty-three of
the 48 families with a known VHL germline mutation and
15 of the 18 LFS families with a known p53 germline
mutation were eligible for the study. Families were ineli-
gible if no adult family members were still alive or residing
in the Netherlands.
Questions on PGD were posed to the high risk family
members (proven carriers, clinical diagnosis, individuals at
50% risk) 16 years of age or older, and to their partners.
Individuals who were not aware that VHL or LFS runs in
their family were excluded from the study. Family mem-
bers were recruited between August 2006 and February
2008. The study was approved by the medical ethics
committees of all participating hospitals.
Procedure
Eligible family members received a letter of invitation
through their clinical geneticist, along with an information
leaflet about the study, a consent form, a questionnaire and
a prepaid return envelope. High risk family members who
were not registered at a clinical genetics centre were
invited through a registered family member. Consenting
family members were asked to invite their partner to par-
ticipate in the study. Adult carriers were also invited to
include their children aged 16–18 years.
Measures
Study participants were asked to complete a self-report ques-
tionnaire including questions on sociodemographics, personal
and family medical history, psychosocial variables, and attitude
towards the use of pre-implantation genetic diagnosis.
Dependent variable
Attitude towards pre-implantation genetic diagnosis After
a short introduction about PGD (see Textbox 1),
respondents were asked the following question: ‘‘Would
you consider the use of PGD if this would be/ would have
been available to you?’’ (response categories: yes/no/
unsure). Additionally, respondents were asked to rate the
advantages and disadvantages of PGD by ticking a list of
five possible advantages and disadvantages.
Independent variables
Factors possibly related with an attitude towards the use of
PGD were selected based on the literature and on clinical
experience [22–24].
Sociodemographics and personal medical history Age,
gender, marital status, educational level, religion, number
of children and current desire to have children, and per-
sonal history of VHL or LFS were assessed via self-report.
Family history of VHL/LFS Participants were asked
whether and, if so, how many close relatives (parents,
siblings and children) were clinically and/or genetically
diagnosed with VHL or LFS, and their age when they were
first confronted with the VHL/LFS-related illness of a close
family member. Parallel questions were posed regarding
death of a family member related to VHL/LFS.
Psychosocial characteristics Cancer worries, perceived
risk, feelings of guilt towards (future) children and syn-
drome-specific distress were assessed with standardized
self-report questionnaires (see Table 1).
Statistical analysis
Descriptive statistics were generated regarding the attitudes
of study participants towards PGD. Univariate analyses
using chi-square, Fisher’s exact test and Student’s t-test
were used to determine which sociodemographic, clinical
and psychosocial variables are related significantly to the
expressed attitude towards PGD. Initially, all analyses were
carried out for the VHL and LFS subgroups separately.
However, because attitudes toward PGD did not differ
significantly as a function of hereditary cancer syndrome,
the results are reported for the total sample.
Textbox 1 Explanation of PGD towards study participants
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Results
Response
In total, 179 of the 216 invited individuals (83%) from 9
LFS and 36 VHL families completed the questionnaire,
including 95 (a)symptomatic carriers, 34 family members
at 50% risk and 50 partners. There were no statistically
significant differences between respondents and non-
respondents in sociodemographic or clinical background
variables.
Sample characteristics
Characteristics of the study sample are shown in Table 2.
Approximately two-thirds of the respondents were VHL
family members, and one-third LFS family members. The
respondents’ age ranged between 16 and 75 years (mean =
39.9 years; SD = 14.0 years). Gender and percentage in
the childbearing age range (aged 40 or younger) were
equally distributed. The majority of the sample indicated a
religious affiliation, with Catholicism being the most pre-
valent religion (34%).
Family members’ attitudes towards PGD
None of the participants had used PGD. Thirty-five percent
of the 129 VHL/LFS family members indicated that they
would consider the use of PGD if this would be/would have
been a possibility for them, 27% was uncertain, and 38%
would not use PGD.
As can be seen in Table 3, a current desire to have children
was related significantly to a positive attitude towards PGD,
with those with such plans being more likely to express an
intention to use PGD than those without such plans (48 vs.
25%, respectively; P = 0.01). Individuals within the child-
bearing age range tended to have a more positive attitude
towards PGD than those over 40 years of age (41 vs. 26%,
respectively; P = 0.10), as did those without vs. with chil-
dren (43 vs. 29%, respectively; P = 0.09). None of the
medical (e.g., personal history of VHL/LFS, number of
affected first degree relatives) or psychosocial variables
(e.g., cancer worries, syndrome-related distress, feelings of
guilt towards (future) children) were associated significantly
with attitude towards PGD.
Partners’ attitudes toward PGD
Of the 50 partners, one-third would consider the use of
PGD if this would be/would have been a possibility for
them, 11 (22%) were not sure, and 22 (45%) would not use
PGD. None of the sociodemographic or medical variablesT
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were associated significantly with attitudes toward PGD,
although male partners tended to be more positive than
female partners (44 vs. 21%, respectively; P = 0.08).
Consistent with the high risk family members, none of the
psychosocial variables were significantly associated with a
positive attitude towards PGD.
Ratings of advantages and disadvantages of PGD
As shown in Table 4, the most frequently rated perceived
advantage of PGD was avoiding the possibility of a
selective pregnancy termination (32%). The most fre-
quently rated disadvantage of PGD was the fact that the
long-term effects of PGD are unknown (18%). It should be
noted, however, that nearly half of the family members and
partners did not endorse any of the possible advantages of
PGD, and slightly more than two-thirds did not endorse any
of the possible disadvantages of PGD.
Discussion
To our knowledge, this is the first large scale investigation
of the attitudes towards the use of PGD and attitude-
associated characteristics of patients, partners and at high
risk members from families with a known hereditary can-
cer predisposition for Von Hippel-Lindau disease or Li–
Fraumeni Syndrome. Approximately one-third of the
family members and their partners expressed a positive
attitude towards the use of PGD. Those family members
with a current desire to have children were significantly
more likely to have such a positive attitude. Approximately
half of the family members and partners contemplating a
future pregnancy would, based on their current knowledge,
consider the use of PGD. No other sociodemographic,
medical or psychosocial variables were associated signifi-
cantly with a positive attitude towards PGD.
Concern has been expressed that the availability of PGD
for cancer susceptibilities could, in time, result in a sig-
nificant increase in the number of PGD requests for a
growing number of diseases which, by objective standards,
might be perceived to be less severe; the so called ‘slippery
slope’ argument. A 10 year evaluation from the single,
certified PGD centre in the Netherlands found that, fol-
lowing an informational intake session and/or the provision
of written materials, 44% of individuals declined the use of
PGD [25] (reasons for decline e.g.: (a) invasive procedure
(b) low success rate personal communication de Die &
Geraedts, single PGD centre the Netherlands). Therefore,
although half of those with a current desire to have children
would consider the use of PGD, in practice only a subset
will eventually opt for PGD. In the past it has also been
observed in requests for prenatal diagnosis (PND) that the
actual uptake was lower than the expected requests. For
example, Adams et al. [22] reported that 18% of Hun-
tington disease carriers used PND, while based on earlier
survey data 65% was expected to do so. In previous studies
of high risk HBOC en FAP family members, of those
contemplating a future pregnancy, 14% (1:7) to 100% (9:9)
indicated that they would consider the use of PGD [11–13].
However, the sample sizes in these studies were too small
to draw firm conclusions on the personal acceptability of
PGD for these hereditary cancer predispositions. Based on
our study results, and on the available literature, it is not
expected that making PGD available to members of
hereditary cancer families will result in a very large uptake
of the procedure. A more significant uptake of PGD may be
expected when success rates of PGD increase and when the
possible long-term health risks for the newborns have been
demonstrated to be negligible.
The majority of participants in our study did not endorse
any specific advantages or disadvantages of PGD. This
may have been due to limited knowledge about PGD. The
Table 2 Characteristics of respondents (N = 179)
N (%)
Syndrome
Li–Fraumeni Syndrome (LFS) 62 (35)
Von Hippel-Lindau disease (VHL) 117 (65)
Personal VHL/LFS status
Carriers 95 (53)
50% at-risk 34 (19)
Partners 50 (28)
Age (mean ± SD) 39.9 ± 14.0
Childbearing age
Yes (B40) 89 (50)
No ([40) 90 (50)
Gender
Male 91 (51)
Female 88 (49)
Marital status
Married/living together 140 (79)
Single 38 (21)
Missing 1
Children (Yes) 103 (58)
Educational level
Low 44 (25)
Moderate 93 (52)
High 42 (23)
Religion
Protestant 19 (11)
Dutch reformed (Calvinist) 15 (8)
Catholic 61 (34)
Other 27 (15)
None 57 (32)
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number of participants who were familiar with PGD prior
to participating in the current study is unknown. An earlier
study in the Netherlands of individuals with other heredi-
tary conditions for which the use of PGD is permitted,
reported that approximately half of respondents was unfa-
miliar with PGD [26]. Similarly, Quinn et al. [13] reported
that the majority of the high risk HBOC conference
attendees were unaware of PGD before they participated in
the study. Similar percentages may be expected for
Table 3 Attitude of high risk family members towards pre-implan-
tation genetic diagnosis (N = 119)
Would use
PGD N (%)
Would not
use or unsure
about using
PGD N (%)
P-value
Total 41 (35) 78 (65)
Sociodemographics
Gender
Male 22 (36) 39 (64) .70
Female 19 (33) 39 (67)
Education
Low 8 (27) 22 (73) .27
Moderate 20 (33) 41 (67)
High 13 (46) 15 (54)
Age (mean ± SD) 36.7 (12.6) 39.4 (14.2) .31
Childbearing age
Yes (B40 years) 27 (41) 39 (59) .10
No ([40 years) 14 (26) 39 (74)
Children
Yes 18 (28) 47 (72) .09
No 23 (43) 31 (57)
Current desire to have children
Yes/maybe 23 (48) 25 (52) .01
No 18 (25) 53 (75)
Religion
Protestant 5 (45) 6 (55)
Dutch reformed 1 (10) 9 (90)
Catholic 18 (39) 28 (61) .45
Other 6 (32) 13 (68)
None 11 (33) 22 (67)
Medical
Syndrome
Von Hippel-Lindau 26 (33) 53 (67) .62
Li–Fraumeni Syndrome 15 (38) 25(62)
DNA status
(a)symptomatic carrier 31 (34) 59 (66) .99
At 50% risk 10 (35) 19 (65)
Personal history of VHL/LFS
Yes 26 (37) 44 (63) .46
No 15 (31) 34 (69)
Affected first degree relativea
None 9 (43) 12 (57) .34
During childhood
(\13 years)
18 (39) 28 (61)
During adolescence
(13–20 years)
6 (35) 11 (65)
During adulthood
([20 years)
7 (22) 25 (78)
3 missing cases – –
Table 3 continued
Would use
PGD N (%)
Would not
use or unsure
about using
PGD N (%)
P-value
Number of affected first degree relatives
None 4 (57) 3 (43)
1–2 16 (35) 30 (65) .28
3 or more 15 (28) 38 (72)
5 missing cases – –
Death first degree relativea
None 22 (39) 34 (61) .45
During childhood
(\13 years)
5 (28) 13 (72)
During adolescence
(13–20 years)
7 (44) 9 (56)
During adulthood
([20 years)
7 (25) 21 (75)
1 missing case – –
Number deceased first degree relatives
None 22 (41) 32 (59)
1–2 14 (29) 35 (71) .42
3 or more 4 (33) 8 (67)
4 missing cases – –
Psychosocial
Cancer worries (mean ± SD) 14.7 ± 4.5 14.2 ± 4.9 .57
IES-intrusion (mean (sd))
Low 27 (35) 51 (65) .80
Moderate 9 (31) 20 (69)
High 5 (42) 7 (58)
Risk perception of developing a tumor
Low 6 (25) 18 (75)
Moderate 19 (42) 26 (58) .34
High 16 (33) 32 (67)
Guilt towards (future) children
Never/Sometimes 29 (36) 52 (64) .55
Often/almost always 11 (42) 15 (58)
Partners in separate analyses; 10 missing cases
a Developmental phase of participant when they first experienced the
diagnosis or death of a first degree relative
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members from families with other known hereditary cancer
predispositions. Although we described the technique of
PGD (see Textbox 1), the information might have been too
limited for some respondents to form an opinion. Those
who expressed an opinion rated the avoidance of a possible
selective pregnancy termination as the most important
advantage. In a study by Lavery et al. [27] among carriers
of Cystic Fibrosis, X-linked disorders and chromosomal
disorder who underwent PGD, this was the primary factor
motivating individuals to opt for PGD. The most frequent
rated disadvantage was the fact that long term effects of the
procedure are as yet unknown.
In our opinion, clinical geneticists and counselors should
carefully consider informing individuals undergoing
genetic counseling for serious hereditary cancer syndromes
about the available reproductive options, including PGD.
Ultimately, as recommended by the European Society for
Human Reproduction & Embryology (ESHRE) and the
European Society for Human Genetics (ESHG), it may be
advisable to make reproductive options equally available
and accessible throughout Europe [28].
Informing counselees about PGD can be done via
written educational materials, but preferably should also be
combined, where appropriate, with counseling by a clinical
geneticist. For example, information leaflets about the
possible reproductive options could be provided at the time
of clinical diagnosis or genetic testing to individuals with a
current or future desire to have children. Advantages as
well as disadvantages of each option could be outlined, and
counselees could be actively encouraged to contact their
counselor for more detailed information. Increased
awareness of reproductive options, including PGD, might
also reduce the number of ‘silent sufferers’ who chose not
to have children because of fear of transmitting the pre-
disposition to their offspring. Based on the results of our
study, there is no indication that psychosocial factors, such
as cancer worries or cancer-related distress, are associated
significantly with interest in undergoing PGD. Rather, it is
the simple desire to have children that motivates such
interest. Nevertheless, we would recommend monitoring
the effect of undergoing PGD on individuals’ psychosocial
health and well-being.
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